Journal of Medico – Antidyslipidemic Therapy and New LDL Cholesterol Target Values

Journal of Medico – Antidyslipidemic Therapy and New LDL Cholesterol Target Values

The Portuguese Congress of Cardiology 2022 is invited to take part as a speaker within the “Module 2: New Perspectives on the Treatment of Coronary Diseases in 2022” of the Update Cycle, Ricardo Fontes-Carvalho, Director of the Department of Cardiology on the Centro Hospitalar de Vila Nova de Gaiaol / Esp. The significance of controlling and the position of varied anti-dyslipidemic remedies in sufferers with cardiovascular threat had been mentioned.

“Nowadays, with meta-evaluation and Mendelian randomization research, there may be very sturdy proof of a causal hyperlink between LDL ldl cholesterol elevation and the event of atherosclerosis,” Ricardo Fontes-Carvalho started, referring to how this premise has already been established. In worldwide pointers.

Regarding the administration of dyslipidemia, the 2019 pointers of the European Society of Cardiology (ESC) discuss with “LDL ldl cholesterol is a wonderful biomarker and therapeutic goal”, which was famous by audio system and critics. As a consequence of the proof, “pointers started to advocate growing the LDL ldl cholesterol goal values ​​more and more, which modifications the cardiovascular threat within the affected person in query,” he underlined.

However, Ricardo Fontes-Carvalho warns of a “hole between medical trials and pointers and the proof that this information is utilized in medical follow”, main consultants to name dyslipidemia a “dangerous relative of cardiovascular inhibition.” . In truth, he defined, “According to the research knowledge, in distinction to hypertension and diabetes, it’s estimated that solely 3% of excessive-threat sufferers and 7% of excessive-threat sufferers have managed LDL levels of cholesterol. Held in Latino, Portugal “.

As Ricardo Fontes-Carvalho explains about these figures, “regardless of efficient therapy modalities and excessive cardiovascular threat, the bulk of the inhabitants studied had been handled with low-depth remedies”.

To illustrate the administration of dyslipidemia, the medical case was mentioned, highlighting the next as cardiovascular threat components: arterial hypertension, sort II diabetes, smoking and dyslipidemia, historical past of ischemic stroke, and acute myocardial an infection. The lipid profiles introduced on the time of admission had been as follows:

  • Total ldl cholesterol = 260 mg / dl,
  • HDL ldl cholesterol = 35 mg / dl
  • LDL ldl cholesterol = 199 mg / dl
  • Non-HDL ldl cholesterol = 225 mg / dl

With viewers participation, it was concluded that the advisable remedy on the time of discharge was a mix of excessive-depth statins with ezetimib. “However, to realize the advisable LDL-ldl cholesterol goal values ​​(<55mg / dl) and thus obtain an 87% discount within the threat of cardiovascular occasions, an ideal discount of 144 mg / dl can be required," he famous. Related to worth. "

Ricardo Fontes-Carvalho warns of this level: “While pointers advocate beginning excessive-depth statin remedy, after defining LDL-ldl cholesterol goal worth, in addition they advocate beginning remedy that enables LDL-ldl cholesterol to succeed in its advisable goal worth. “.

Therefore, on this case, a therapeutic mixture of atorvastatin 40 mg and ezetimib was chosen, which, after eight weeks of therapy, was capable of successfully decrease levels of cholesterol to the next ranges:

  • Total ldl cholesterol = 176 mg / dl
  • HDL ldl cholesterol = 39 mg / dl
  • LDL ldl cholesterol = 118 mg / dl
  • Non-HDL ldl cholesterol = 137 mg / dl

The heart specialist famous that, regardless of vital reductions in LDL ldl cholesterol, it was not potential to succeed in the advisable goal worth, making the affected person eligible for remedy with PCSK9 inhibitors.

On this level, Ricardo Fontes-Carvalho referred to the “Practical Guide to the Use of PCSK9 Inhibitors in Portugal” by the Portuguese Society of Cardiology, the Portuguese Society of Atherosclerosis, and the Portuguese Society of Internal Medicine. Portuguese Society of Endocrinology, Diabetes and Metabolism.

With a view to the long run, creating new anti-dyslipidemic therapies had been additionally briefly addressed, together with “bempedoic acid 180 mg, which, as a substitute for statins, acts on the stage of ATP citrate lysine and inclusions, prevents degradation of LDL ldl cholesterol and LDL ldl cholesterol solely.” Injections can considerably decrease LDL ldl cholesterol (40-50%) ”.

Finally, Ricardo Fontes-Carvalho strengthened the idea of “decrease, the earlier and the longer, the higher” within the context of LDL ldl cholesterol, and the notion that “decreasing incidence is extra essential than decreasing ldl cholesterol values.” Cardiovascular Diseases, Implementation and Maintenance of Patient Accessibility for Treatment ”.

.

Leave a Comment

Your email address will not be published.